ArticleJournal of hypertension2022
Comprehensive biomarker profiling of hypertension in 36 985 Finnish individuals.
Article in Journal of hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Searching for Metabolic Markers for Hypertension in Human Urine.Molecules (Basel, Switzerland) · 2026Article
- Value of Multiomics Over Clinical Risk Factors in Hypertension Prediction.Hypertension (Dallas, Tex. : 1979) · 2026Article
- The association between the gut microbiome and 24-h blood pressure measurements in the SCAPIS study.Communications medicine · 2025Article
- Nuclear Magnetic Resonance Analysis Seeking for Metabolic Markers of Hypertension in Human Serum.Molecules (Basel, Switzerland) · 2025Article
- Understanding Hypertension: A Metabolomic Perspective.Biology · 2025Review
- Combined and mediating effects of remnant cholesterol and renal function on hypertension risk in Chinese middle-aged and elderly people.Frontiers in endocrinology · 2025Article
- Remnant cholesterol, not LDL cholesterol, is associated with the risk of hypertension in the middle-aged and elderly population: Bushehr Elderly Health cohort.Frontiers in cardiovascular medicine · 2025Article
- Article
- Association between remnant cholesterol, metabolic syndrome, and cardiovascular disease: post hoc analysis of a prospective national cohort study.European journal of medical research · 2023Article
- Metabolic profiling of MRI-measured liver fat in the UK Biobank.Obesity (Silver Spring, Md.) · 2023Article
- Remnant cholesterol associates with hypertension beyond low-density lipoprotein cholesterol among the general US adult population.Frontiers in endocrinology · 2023Article
- Comprehensive biomarker profiling of hypertension in 36 985 Finnish individuals.Journal of hypertension · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrevious studies on the association between metabolic biomarkers and hypertension have been limited by small sample sizes, low number of studied biomarkers, and cross-sectional study design. In the largest study to date, we assess the cross-sectional and longitudinal associations between high-abundance serum biomarkers and blood pressure (BP).
methodsWe studied cross-sectional (N = 36 985; age 50.5 ± 14.2; 53.1% women) and longitudinal (N = 4197; age 49.4 ± 11.8, 55.3% women) population samples of Finnish individuals. We included 53 serum biomarkers and other detailed lipoprotein subclass measures in our analyses. We studied the associations between serum biomarkers and BP using both conventional statistical methods and a machine learning algorithm (gradient boosting) while adjusting for clinical risk factors.
resultsFifty-one of 53 serum biomarkers were cross-sectionally related to BP (adjusted P < 0.05 for all). Conventional linear regression modeling demonstrated that LDL cholesterol, remnant cholesterol, apolipoprotein B, and acetate were positively, and HDL particle size was negatively, associated with SBP change over time (adjusted P < 0.05 for all). Adding serum biomarkers (cross-sectional root-mean-square error: 16.27 mmHg; longitudinal: 17.61 mmHg) in the model with clinical measures (cross-sectional: 16.70 mmHg; longitudinal 18.52 mmHg) improved the machine learning model fit. Glucose, albumin, triglycerides in LDL, glycerol, VLDL particle size, and acetoacetate had the highest importance scores in models related to current or future BP.
conclusionOur results suggest that serum lipids, and particularly LDL-derived and VLDL-derived cholesterol measures, and glucose metabolism abnormalities are associated with hypertension onset. Use of serum metabolite determination could improve identification of individuals at high risk of developing hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.